PTC Therapeutics, Inc.

PTCT Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
PTCT Income Statement
PTCT Balance Sheet
PTCT Cash Flow
Congress Trading

Recent trades of PTCT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
PTCT Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
PTCT Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
PTCT Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by PTCT's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $90,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $100,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $320,000 Apr 22, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $170,000 Jan 22, 2024 Issue: Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $170,000 Oct 20, 2023 Issue: Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $190,000 Jul 20, 2023 Issue: Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $570,000 Apr 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $160,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $190,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $200,000 Jul 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $370,000 Apr 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $190,000 Apr 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $180,000 Oct 20, 2021 Issue: None
  • $180,000 Jul 20, 2021 Issue: None
  • $180,000 Apr 20, 2021 Issue: None
  • $180,000 Jan 21, 2021 Issue: None
  • $180,000 Oct 29, 2020 Issue: None
  • $50,000 Jul 20, 2020 Issue: Health Issues
  • $50,000 Apr 26, 2020 Issue: Health Issues
  • $50,000 Feb 25, 2020 Issue: Health Issues
  • $20,000 Apr 17, 2019 Issue: Budget/Appropriations
  • $40,000 Apr 17, 2019 Issue: Budget/Appropriations
  • $30,000 Jan 22, 2019 Issue: Budget/Appropriations
  • $60,000 Jan 22, 2019 Issue: Budget/Appropriations
  • $10,000 Jan 16, 2019 Issue: None
  • $10,000 Oct 18, 2018 Issue: Health Issues Medicare/Medicaid
  • $30,000 Oct 18, 2018 Issue: Budget/Appropriations
  • $60,000 Oct 18, 2018 Issue: Budget/Appropriations
  • $30,000 Jul 20, 2018 Issue: Budget/Appropriations
  • $60,000 Jul 20, 2018 Issue: Budget/Appropriations
  • $30,000 Apr 20, 2018 Issue: Budget/Appropriations
  • $30,000 Apr 20, 2018 Issue: Budget/Appropriations
  • $30,000 Jan 17, 2018 Issue: Budget/Appropriations
  • $30,000 Jan 17, 2018 Issue: Budget/Appropriations
  • $30,000 Oct 18, 2017 Issue: Budget/Appropriations
  • $30,000 Oct 18, 2017 Issue: Budget/Appropriations
  • $30,000 Aug 09, 2017 Issue: Budget/Appropriations
  • $30,000 Aug 09, 2017 Issue: Budget/Appropriations
  • $30,000 Jul 18, 2017 Issue: Budget/Appropriations
  • $10,000 Apr 20, 2017 Issue: Health Issues
  • $30,000 Apr 19, 2017 Issue: Budget/Appropriations
  • $10,000 Jan 19, 2017 Issue: Budget/Appropriations
  • $30,000 Jan 12, 2017 Issue: Budget/Appropriations
  • $30,000 Oct 20, 2016 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Heteroaryl compounds for treating huntington's disease Nov. 12, 2024
  • Patent Title: Compounds for treating huntington's disease Oct. 01, 2024
  • Patent Title: Method for treating pancreatic cancer Jul. 02, 2024
  • Patent Title: Polymorphic forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Mar. 26, 2024
  • Patent Title: Heterocyclic and heteroaryl compounds for treating huntington's disease Jan. 02, 2024
  • Patent Title: 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Dec. 12, 2023
  • Patent Title: Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione Oct. 17, 2023
  • Patent Title: Compounds for treating huntington's disease Oct. 10, 2023
  • Patent Title: Compounds for treating spinal muscular atrophy Sep. 12, 2023
  • Patent Title: 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Sep. 05, 2023
  • Patent Title: Methods for modulating rna splicing Jul. 18, 2023
  • Patent Title: Heteroaryl compounds for treating huntington's disease Jun. 27, 2023
  • Patent Title: Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders Jun. 20, 2023
  • Patent Title: 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Jun. 06, 2023
  • Patent Title: Methods for treating huntington's disease May. 02, 2023
  • Patent Title: Method of inhibiting or reducing a viral infection Mar. 28, 2023
  • Patent Title: Methods for modifying rna splicing Mar. 21, 2023
  • Patent Title: Methods for modulating rna splicing Mar. 14, 2023
  • Patent Title: Methods for enriching alpha-tocotrienol from mixed tocol compositions Jan. 24, 2023
  • Patent Title: Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease Nov. 15, 2022
  • Patent Title: Dhodh inhibitor for use in treating hematologic cancers Oct. 04, 2022
  • Patent Title: Compounds for treating huntington's disease Aug. 09, 2022
  • Patent Title: Methods for treating huntington's disease Jul. 26, 2022
  • Patent Title: 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof Jul. 19, 2022
  • Patent Title: Methods for treating huntington's disease Jul. 12, 2022
  • Patent Title: Process for the production of alpha-tocotrienol and derivatives Apr. 26, 2022
  • Patent Title: Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Apr. 19, 2022
  • Patent Title: Methods for enriching alpha-tocotrienol from mixed tocol compositions Nov. 30, 2021
  • Patent Title: Substituted reverse pyrimidine bmi-1 inhibitors Nov. 23, 2021
  • Patent Title: 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Nov. 16, 2021
  • Patent Title: Methods of administering deflazacort therapy Aug. 10, 2021
  • Patent Title: Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers Jun. 01, 2021
  • Patent Title: Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders Apr. 20, 2021
  • Patent Title: 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Apr. 06, 2021
  • Patent Title: Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease Mar. 30, 2021
  • Patent Title: Processes for the preparation of substituted tetrahydro beta-carbolines Mar. 16, 2021
  • Patent Title: Gene therapy for aadc deficiency Jan. 26, 2021
  • Patent Title: Methods for treating huntington's disease Jan. 05, 2021
  • Patent Title: Methods for treating huntington's disease Dec. 29, 2020
  • Patent Title: Compounds for treating spinal muscular atrophy Dec. 01, 2020
  • Patent Title: Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy Dec. 01, 2020
  • Patent Title: Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Aug. 25, 2020
  • Patent Title: Methods for enriching alpha-tocotrienol from mixed tocol compositions Aug. 18, 2020
  • Patent Title: 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof Aug. 11, 2020
  • Patent Title: Treatment of pervasive developmental disorders with redox-active therapeutics Aug. 11, 2020
  • Patent Title: Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders Jul. 07, 2020
  • Patent Title: Methods for modulating the amount of rna transcripts Jun. 23, 2020
  • Patent Title: Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease Jun. 09, 2020
  • Patent Title: Methods for modulating rna splicing Jun. 02, 2020
  • Patent Title: Substituted pyridine and pyrazine bmi-1 inhibitors Mar. 10, 2020
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of PTCT in WallStreetBets Daily Discussion

PTCT News

Recent insights relating to PTCT

CNBC Recommendations

Recent picks made for PTCT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PTCT

PTCT Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view PTCT Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top